dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-29 and is reviewed periodically as new material appears.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
The Cape cobra (Naja nivea) is regarded as one of the most dangerous species of cobra in Africa, by virtue of its potent venom and frequent occurrence around houses. The venom of this snake tends to be thick and syrupy in consistency and dries into shiny pale flakes, not unlike yellow sugar. The Cape cobras venom is made up of potent postsynaptic neurotoxins and might also contain cardiotoxins, that affect the respiratory system, nervous system, and the heart. The mouse SC LD50 for this species' venom is 0.72, while the IV and IP LD50 values are 0.4 mg/kg and 0.6 mg/kg, respectively. The average venom yield per bite is 100 to 150 mg according to Minton. The mortality rate for untreated bites is not exactly known, but is thought to be high. This can be because of various factors including the amount of venom injected, psychological state of the bitten subject and the penetration of one or both fangs. Mechanical ventilation and symptom management is often enough to save a victim's life, but cases of serious Cape cobra envenomation will require antivenom. When death does occur, it normally takes anywhere from an hour (in severe cases) to ten hours (or more) and it is often as a result of respiratory failure, because of the onset of paralysis. The antivenom used in case of a bite is a polyvalent antivenom produced by the South African Institute of Medical Research (SAIMR).
The two substrates of this enzyme are D-fructose (shown in its keto form) and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). ts products are 5-dehydro-D-fructose, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-fructose:NADP+ 5-oxidoreductase. Other names in common use include 5-ketofructose reductase (NADP+), 5-keto-D-fructose reductase (NADP+), fructose 5-(nicotinamide adenine dinucleotide phosphate), dehydrogenase, D-(-)fructose:(NADP+) 5-oxidoreductase, and fructose 5-dehydrogenase (NADP+).
In 1990, the USDA's Food Safety and Inspection Service (FSIS) approved the use of the technology for manufacturing finely textured meat. At the time of its approval, the FSIS called the remaining product "meat", although one FSIS microbiologist dissented, arguing it contained both muscle and connective tissue. In 1994, in response to public health concerns over pathogenic E. coli in beef, the founder of BPI, Eldon Roth, began work on the "pH Enhancement System", which disinfects meat using injected anhydrous ammonia in gaseous form, rapid freezing to 28 °F (−2 °C), and mechanical stress. In 2001, the FSIS approved the gaseous disinfection system as an intermediate step before the roller press freezer, and approved the disinfected product for human consumption, as an additive. The FSIS agreed with BPI's suggestion that ammonia was a "processing agent" which did not need to be listed on labels as an ingredient. FSIS microbiologists Carl Custer and Gerald Zirnstein stated that they argued against the product's approval for human consumption, saying that it was not "meat" but actually "salvage", and that the USDA should seek independent verification of its safety, but they were overruled. In 2003, BPI commissioned a study of the effectiveness and safety of the disinfection process; the Iowa State University researchers found no safety concern in the product or in ground beef containing it. The term "pink slime", a reference to the product's "distinctive look", was coined in 2002 by Zirnstein in an internal FSIS e-mail.
Sources: en.wikipedia.org
== Assistants == Nurse aide (CNA) Nurse technician (CNT) Care partner (CP) Medical Assistants Certified Medical Assistant (CMA) Certified Medical Assistant - Admin (CMA-A) Certified Medical Assistant - Clinical (CMA-C) Certified Medical Assistant - Admin and Clinical (CMA-AC) Registered Medical Assistant (RMA) Medical Assistant (MA) Certified Clinical Medical Assistant (CCMA) Certified Medical Administrative Assistant (CMAA) Pharmacy Technician Certified Pharmacy Technician (CPhT)
The method is widely applied, particularly by using automatic parallel synthesizers. Although the parallel method is much slower than the real combinatorial one, its advantage is that it is exactly known which peptide or other compound forms on each pin. Further procedures were developed to combine the advantages of both split-mix and parallel synthesis. In a method described by two groups, the solid support was enclosed into permeable plastic capsules together with a radiofrequency tag that carried the code of the compound to be formed in the capsule. The procedure was carried out similar to the split-mix method. In the split step, however, the capsules were distributed among the reaction vessels according to the codes read from the radiofrequency tags of the capsules. A different method for the same purpose was developed by Furka et al. named "string synthesis". In this method, the capsules carry no code. They are strung like pearls in a necklace and placed into the reaction vessels in stringed form. The identity of the capsules, as well as their contents, are stored by their position occupied on the strings. After each coupling step, the capsules are redistributed among new strings according to definite rules.
=== Detection === Recent usage of kava has been documented in forensic investigations by quantitation of kavain in blood specimens. The principal urinary metabolite, conjugated 4'-OH-kavain, is generally detectable for up to 48 hours.
=== Legal status === In June 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Imreplys, intended for the treatment of people with hematopoietic acute radiation syndrome (H-ARS) following acute exposure to myelosuppressive doses of radiation. The applicant for this medicinal product is Partner Therapeutics Ltd.
Sources: en.wikipedia.org
However, the results of the 2012 presidential elections gave the PS wins in both districts with a smaller margin in the 7th (Hollande: 51.71% / Sarkozy: 48.29%) than in the 8th (Hollande 64.21% / Sarkozy: 35.79%).
== History == The first frog egg extract was reported in 1983 by Lohka and Masui. This pioneering work used eggs of the Northern leopard frog Rana pipiens to prepare an extract. Later, the same procedure was applied to eggs of Xenopus laevis, becoming popular for studying cell cycle progression and cell cycle-dependent cellular events. Extracts derived from eggs of the Japanese common toad Bufo japonicus or of the Western clawed frog Xenopus tropicalis have also been reported.
Supercritical water oxidation Photodegradation Sonochemical oxidation Electrochemical oxidation Plasma treatment Hydrothermal alkaline treatment Incineration Private and public sector applications of one or more of these methodologies above are being applied to remediation sites throughout the United States and other international locations. The U.S.-based Interstate Technology and Regulatory Council (ITRC) has undertaken an extensive evaluation of ex-situ and in-situ treatment technologies for PFAS-impacted liquid matrices. These technologies are divided into field-implemented technologies, limited application technologies, and developing technologies and typically fit into one of three technology types, namely separation, concentration, and destruction.
Crystallization of ubiquitin protein was successfully done using racemic crystallography. Crystallization of either D-ubiquitin or L-ubiquitin alone is difficult, whereas a racemic mixture of D-ubiquitin and L-ubiquitin was readily crystallized and diffraction quality crystals were obtained overnight in almost half the conditions tested in a standard commercial crystallization screen. Crystallization of racemates of disulfide-containing microprotein molecules was used to determine the structure of trypsin inhibitor SFTI-1 (14 amino acids,1 disulfide), conotoxin cVc1.1 (22 amino acids, 2 disul-fides) and cyclotide kB1 (29 amino acids, 3 disulfides). Using X-ray diffraction, it was found that the racemates crystallized in the centrosymmetric spacegroups P3(bar), Pbca and P1(bar). Interestingly, achiral "'peptoid'" chains were found to fold as racemic pairs and crystallize in highly preferred centrosymmetric space groups. A high-resolution crystal structure of the racemate of a heterochiral D-protein complex with vascular endothelial growth factor A (VEGF-A). The mirror image D-protein form of VEGF-A was used in phage display to identify a 56 residue L-protein binder with nanomolar affinity; the chemically synthesized D-protein binder had the same affinity for the L-protein form of VEGF-A. A mixture of chemically synthesized proteins consisting of D-VEGF-A, L-VEGF-A, and two equivalents each of the D-protein binder and L-protein binder, gave racemic crystals in the centrosymmetric space group P21/n.
==== Glycol chitosan ==== Enzymatic activity of intact and PEGylated lysozyme can be evaluated using glycol chitosan by reacting 1 mL of 0.05% (w/v) glycol chitosan in 100 mM of pH 5.5 acetate buffer and 100 μL of the intact or PEGylated protein at 40 °C for 30 min and subsequently adding 2 mL of 0.5 M sodium carbonate with 1 μg of potassium ferricyanide. The mixture is immediately heated, boiled for 15 minutes, and cooled for spectral analysis at 420 nm. As the enzymatic activity to hydrolyze β-1,4- N-acetylglucosamine linkage was retained after PEGylation, there was no decay in the enzymatic activity by increasing the degree of PEGylation.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.